# GMAB catalysts: GENMAB A/S PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/gmab/catalysts

> GENMAB A/S (GMAB) has 32 upcoming catalysts. The next is the TEPKINLY (epcoritamab) primary completion, March 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | GENMAB A/S |
| Ticker | GMAB (Nasdaq) |
| SEC CIK | 1434265 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/gmab |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2023 | [TEPKINLY (epcoritamab) FDA approval](https://sec-api.dev/pdufa/epcoritamab) | GMAB |  | completed, approved | "Epcoritamab was approved by the FDA and Japan MHLW in May 2023 and September 2023, respectively, and is marketed in the U.S. and Japan under the tradename EPKINLY." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434265/000119312525277733/d768286dex993.htm)) |
| May 19, 2023 | [Epkinly (epcoritamab-bysp) FDA approval](https://sec-api.dev/pdufa/epcoritamab-bysp) | GMAB |  | completed, approved | "Epkinly \| epcoritamab-bysp \| 5/19/2023 \| To treat relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapy" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| Jun 2023 | [GENMAB A/S topline data readout](https://sec-api.dev/companies/gmab/catalysts) | GMAB |  | completed, positive | "In June 2023 we announced positive topline results from this cohort." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1434265/000155837025000846/gmab-20241231x20f.htm)) |
| Jun 2024 | [EPKINLY (epkinly) FDA approval](https://sec-api.dev/pdufa/epkinly) | GMAB |  | completed, approved | "In June 2024, EPKINLY monotherapy was granted accelerated approval by the FDA for the treatment of R/R FL following two or more lines of systemic therapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434265/000143426525000095/gmab_20251118xex99d1.htm)) |
| Jun 2024 | [TEPKINLY (epcoritamab) FDA approval](https://sec-api.dev/pdufa/epcoritamab) | GMAB | with relapsed or refractory FL | completed, approved | "In June 2024, the U.S. FDA approved a second indication for EPKINLY (epcoritamab-bysp), specifically for the treatment of adults with relapsed or refractory FL after two or more lines of systemic therapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434265/000155837025000831/gmab-20241231xex99d1.htm)) |
| June 26, 2024 | [Epkinly (epcoritamab-bysp) label expansion decision](https://sec-api.dev/pdufa/epcoritamab-bysp) | GMAB |  | completed, approved | "BLA761324 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20240626, review_priority PRIORITY; sponsor_name GENMAB US, INC.; product EPKINLY (EPCORITAMAB-BYSP)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761324%22)) |
| Nov 2024 | [DARZALEX (daratumumab) NDA/BLA submission](https://sec-api.dev/pdufa/daratumumab) | GMAB |  | completed | "In November 2024, J&J also submitted a sBLA to the FDA seeking approval for daratumumab SC in this indication in the U.S. Please consult the European Summary of Product Characteristics for DARZALEX and DARZALEX SC and the U.S. Prescribing Information for DARZALEX and DARZALEX FASPRO for the labeled indication and safety information." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1434265/000143426525000063/gmab-20250630.htm)) |
| October 13, 2025 | [TEPKINLY (epcoritamab) primary completion](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-cell Lymphoma | completed | "NCT04628494 (A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Genmab; Results First Posted 2026-11-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04628494)) |
| October 13, 2025 | [TEPKINLY (epcoritamab) primary completion](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-Cell Lymphoma | completed | "NCT07226752 (A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Genmab; Results First Posted 2026-11-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226752)) |
| November 18, 2025 | [TEPKINLY (epcoritamab) FDA approval](https://sec-api.dev/pdufa/epcoritamab) | GMAB | relapsed or refractory | completed, approved | "COPENHAGEN, Denmark; November 18, 2025 - Genmab A/S (Nasdaq: GMAB) announced today that EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) was approved by the U.S. Food and Drug Administration (FDA) for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434265/000143426525000095/gmab_20251118xex99d1.htm)) |
| November 18, 2025 | [Epkinly (epcoritamab-bysp) label expansion decision](https://sec-api.dev/pdufa/epcoritamab-bysp) | GMAB |  | completed, approved | "BLA761324 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20251118, review_priority PRIORITY; sponsor_name GENMAB US, INC.; product EPKINLY (EPCORITAMAB-BYSP)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761324%22)) |
| November 30, 2025 | [TEPKINLY (epcoritamab) PDUFA date](https://sec-api.dev/pdufa/epcoritamab) | GMAB |  | completed, approved | "•U.S. FDA has accepted for priority review new supplemental Biologics License Application (sBLA) for epcoritamab plus R2, with action date of November 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434265/000143426525000061/gmab_20250807xex99d1.htm)) |
| March 27, 2026 | [Epkinly (epcoritamab-bysp) label expansion decision](https://sec-api.dev/pdufa/epcoritamab-bysp) | GMAB |  | completed, approved | "BLA761324 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20260327, review_priority STANDARD; sponsor_name GENMAB US, INC.; product EPKINLY (EPCORITAMAB-BYSP)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761324%22)) |
| May 15, 2026 | [Acasunlimab primary completion](https://sec-api.dev/pdufa/acasunlimab) | GMAB |  | withdrawn | "NCT06984328 (Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-05-15 (ACTUAL); Lead Sponsor Genmab; Results First Posted 2026-09-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06984328)) |
| June 10, 2026 | [TEPKINLY (epcoritamab) primary completion](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-Cell Lymphoma | withdrawn | "NCT05660967 (Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-06-10 (ACTUAL); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05660967)) |
| August 18, 2026 | [Rina-s primary completion](https://sec-api.dev/pdufa/rina-s) | GMAB | Platinum-resistant Ovarian Cancer | completed | "NCT06619236 (Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-18 (ACTUAL); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06619236)) |
| Aug to Nov 2026 | [Rina-s topline data readout](https://sec-api.dev/pdufa/rina-s) | GMAB | Platinum-resistant Ovarian Cancer | scheduled | "NCT06619236 (Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-18 (ACTUAL); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06619236)) |
| October 5, 2026 | [TEPKINLY (epcoritamab) topline data readout](https://sec-api.dev/pdufa/epcoritamab) | GMAB |  | completed, positive | "Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of 2 to 5." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434265/000143426526000132/gmab_20261015xex99d1.htm)) |
| October 23, 2026 | [Rinatabart topline data readout](https://sec-api.dev/pdufa/rinatabart) | GMAB | platinum-resistant ovarian cancer | completed, positive | "Genmab A/S (Nasdaq: GMAB) announced today positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), in patients with platinum-resistant ovarian cancer (PROC) regardless of FRα expression level or prior treatment with mirvetuximab." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434265/000143426526000138/gmab_20261023xex99d1.htm)) |
| October 28, 2026 | [Petosemtamab topline data readout](https://sec-api.dev/pdufa/petosemtamab) | GMAB |  | completed, positive | "Genmab A/S (Nasdaq: GMAB) today announced positive topline results from the global Phase 3 LiGeR-HN1 trial (NCT06525220) evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with pembrolizumab versus pembrolizumab in patients with first-line (1L) PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434265/000143426526000140/gmab_20261028xex99d1.htm)) |
| November 3, 2026 | [TEPKINLY (epcoritamab) topline data readout](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-cell Lymphoma | completed | "NCT04628494 (A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Genmab; Results First Posted 2026-11-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04628494?tab=results)) |
| November 10, 2026 | [TEPKINLY (epcoritamab) topline data readout](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-Cell Lymphoma | completed | "NCT07226752 (A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Genmab; Results First Posted 2026-11-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226752?tab=results)) |
| March 2027 | [TEPKINLY (epcoritamab) primary completion](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-Cell Lymphoma; Classic Follicular Lymphoma | scheduled | "NCT05451810 (A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05451810)) |
| Mar to Jun 2027 | [TEPKINLY (epcoritamab) topline data readout](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-Cell Lymphoma; Classic Follicular Lymphoma | scheduled | "NCT05451810 (A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05451810)) |
| June 2027 | [TEPKINLY (epcoritamab) primary completion](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-Cell Lymphoma | scheduled | "NCT05578976 (A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05578976)) |
| Jun to Sep 2027 | [TEPKINLY (epcoritamab) topline data readout](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-Cell Lymphoma | scheduled | "NCT05578976 (A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05578976)) |
| Jul to Oct 2027 | [Acasunlimab topline data readout](https://sec-api.dev/pdufa/acasunlimab) | GMAB | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | scheduled | "NCT06635824 (Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06635824)) |
| July 2027 | [Acasunlimab primary completion](https://sec-api.dev/pdufa/acasunlimab) | GMAB | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | scheduled | "NCT06635824 (Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06635824)) |
| September 2027 | [Rina-s primary completion](https://sec-api.dev/pdufa/rina-s) | GMAB | Platinum-resistant Ovarian Cancer | scheduled | "NCT07604766 (An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07604766)) |
| Sep to Dec 2027 | [Rina-s topline data readout](https://sec-api.dev/pdufa/rina-s) | GMAB | Platinum-resistant Ovarian Cancer | scheduled | "NCT07604766 (An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07604766)) |
| Nov 2027 to Feb 2028 | [Rina-s topline data readout](https://sec-api.dev/pdufa/rina-s) | GMAB | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT07288177 (Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-22 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07288177)) |
| November 2027 | [Rina-s primary completion](https://sec-api.dev/pdufa/rina-s) | GMAB | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT07288177 (Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-22 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07288177)) |
| January 2028 | [Petosemtamab primary completion](https://sec-api.dev/pdufa/petosemtamab) | GMAB | Head and Neck Squamous Cell Carcinoma | scheduled | "NCT06525220 (A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06525220)) |
| Jan to Apr 2028 | [Petosemtamab topline data readout](https://sec-api.dev/pdufa/petosemtamab) | GMAB | Head and Neck Squamous Cell Carcinoma | scheduled | "NCT06525220 (A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06525220)) |
| February 2028 | [Petosemtamab primary completion](https://sec-api.dev/pdufa/petosemtamab) | GMAB | Head and Neck Squamous Cell Carcinoma | scheduled | "NCT06496178 (A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06496178)) |
| Feb to May 2028 | [Petosemtamab topline data readout](https://sec-api.dev/pdufa/petosemtamab) | GMAB | Head and Neck Squamous Cell Carcinoma | scheduled | "NCT06496178 (A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06496178)) |
| March 2028 | [TEPKINLY (epcoritamab) primary completion](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-Cell Lymphoma | scheduled | "NCT06508658 (A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06508658)) |
| Mar to Jun 2028 | [TEPKINLY (epcoritamab) topline data readout](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-Cell Lymphoma | scheduled | "NCT06508658 (A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06508658)) |
| September 2028 | [Rina-s primary completion](https://sec-api.dev/pdufa/rina-s) | GMAB | Gastrointestinal Cancers | scheduled | "NCT07539311 (Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07539311)) |
| Sep to Dec 2028 | [Rina-s topline data readout](https://sec-api.dev/pdufa/rina-s) | GMAB | Gastrointestinal Cancers | scheduled | "NCT07539311 (Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07539311)) |
| October 2028 | [Rina-s primary completion](https://sec-api.dev/pdufa/rina-s) | GMAB | Ovarian Cancer; Platinum-sensitive Ovarian Cancer; PSOC | scheduled | "NCT07225270 (Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07225270)) |
| Oct 2028 to Jan 2029 | [Rina-s topline data readout](https://sec-api.dev/pdufa/rina-s) | GMAB | Ovarian Cancer; Platinum-sensitive Ovarian Cancer; PSOC | scheduled | "NCT07225270 (Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07225270)) |
| Mar to Jun 2029 | [Petosemtamab topline data readout](https://sec-api.dev/pdufa/petosemtamab) | GMAB | Colorectal Cancer | scheduled | "NCT07775287 (Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-30 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07775287)) |
| March 2029 | [Petosemtamab primary completion](https://sec-api.dev/pdufa/petosemtamab) | GMAB | Colorectal Cancer | scheduled | "NCT07775287 (Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-30 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07775287)) |
| July 2029 | [Petosemtamab primary completion](https://sec-api.dev/pdufa/petosemtamab) | GMAB | Left-sided Colorectal Cancer | scheduled | "NCT07702032 (Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07702032)) |
| Jul to Oct 2029 | [Petosemtamab topline data readout](https://sec-api.dev/pdufa/petosemtamab) | GMAB | Left-sided Colorectal Cancer | scheduled | "NCT07702032 (Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07702032)) |
| August 2029 | [Rina-s primary completion](https://sec-api.dev/pdufa/rina-s) | GMAB | Endometrial Cancer; Recurrent or Progressive Endometrial Cancer | scheduled | "NCT07166094 (Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07166094)) |
| Aug to Nov 2029 | [Rina-s topline data readout](https://sec-api.dev/pdufa/rina-s) | GMAB | Endometrial Cancer; Recurrent or Progressive Endometrial Cancer | scheduled | "NCT07166094 (Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07166094)) |
| December 2029 | [TEPKINLY (epcoritamab) primary completion](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Follicular Lymphoma (FL) | scheduled | "NCT05409066 (Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05409066)) |
| Dec 2029 to Mar 2030 | [TEPKINLY (epcoritamab) topline data readout](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Follicular Lymphoma (FL) | scheduled | "NCT05409066 (Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05409066)) |
| December 2029 | [Rina-s primary completion](https://sec-api.dev/pdufa/rina-s) | GMAB | Platinum-Sensitive Ovarian Cancer; Ovarian Cancer | scheduled | "NCT07564141 (Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07564141)) |
| Dec 2029 to Mar 2030 | [Rina-s topline data readout](https://sec-api.dev/pdufa/rina-s) | GMAB | Platinum-Sensitive Ovarian Cancer; Ovarian Cancer | scheduled | "NCT07564141 (Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07564141)) |
| March 2030 | [Rina-s primary completion](https://sec-api.dev/pdufa/rina-s) | GMAB | Ovarian Cancer | scheduled | "NCT07859215 (Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-03 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07859215)) |
| Mar to Jun 2030 | [Rina-s topline data readout](https://sec-api.dev/pdufa/rina-s) | GMAB | Ovarian Cancer | scheduled | "NCT07859215 (Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-03 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07859215)) |

## Drugs

- [Acasunlimab](https://sec-api.dev/pdufa/acasunlimab): PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC, Cutaneous Melanoma
- [TEPKINLY (epcoritamab)](https://sec-api.dev/pdufa/epcoritamab): with relapsed or refractory fl, relapsed or refractory, Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma
- [Epkinly (epcoritamab-bysp)](https://sec-api.dev/pdufa/epcoritamab-bysp): 
- [EPKINLY (epkinly)](https://sec-api.dev/pdufa/epkinly): 
- [Petosemtamab](https://sec-api.dev/pdufa/petosemtamab): first-line, Head and Neck Squamous Cell Carcinoma, Left-sided Colorectal Cancer, Colorectal Cancer
- [Rina-s](https://sec-api.dev/pdufa/rina-s): Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, Endometrial Cancer, Gastrointestinal Cancers, Platinum-resistant Ovarian Cancer, Platinum-Sensitive Ovarian Cancer
- [Rinatabart](https://sec-api.dev/pdufa/rinatabart): platinum-resistant ovarian cancer

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/gmab/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GMAB catalysts: GENMAB A/S PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/gmab/catalysts

```bibtex
@misc{secapidev_companies_gmab_catalysts_20261116,
  title        = {GMAB catalysts: GENMAB A/S PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/gmab/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_gmab_catalysts_20261116","title":"GMAB catalysts: GENMAB A/S PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/gmab/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
